Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Opioid
No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
FDA approves 'non-opioid' painkillers
Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain," according to the FDA.
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Science News
1h
A new kind of non-opioid painkiller gets FDA approval
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
Hosted on MSN
1h
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Black boxes recovered
New tariffs coming Saturday
IL won’t hire Jan. 6 rioters
Todd exits NBC News
Cause of death revealed
Apologizes for old tweets
Granted legal personhood
Activists call for boycott
Cancerous tumor removed
Tour boat captain sentenced
Navajo men, partner indicted
To again run for Senate?
Top leaders asked to resign
Inmate's transfer blocked
Hamas confirms death
To raise hourly pay
Ground stop amid IT outage
Nashville bids for franchise
Recuses self from Act 10 suit
FDA approves painkiller
S3 release date revealed
US inflation ticked higher
DOJ sues to block deal
Partners w/ US national labs
Olympic gold medalist dies
'As Tears Go By' singer dies
Michigan priest loses license
Weekly jobless claims fall
Confirmed interior secretary
Seeking a new trial
Shiffrin finishes 10th
Related topics
Journavx
Vertex Pharmaceuticals
Food and Drug Administration
Feedback